Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 922 participants.

Also called NCT01031680

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 922 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01031680
Other papers using this trial's data
  • Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension Diabetes care, 2015-07 DOI, PubMed 25852208, PMC4831907 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Canada, Germany, Romania, Slovakia, Spain, Taiwan, Vietnam (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01031680. Randomized; quadruple masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2011-05 (actual). Results posted on 2013-08-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension
Condition
Type 2 Diabetes Mellitus
Condition
Cardiovascular Disease
Condition
Hypertension
Condition
Inadequate Glycaemic Control
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct01031680
Content hash
52dbda51c6cff4dbe0eddbc41986b2952e369c55212d5c7f22a6bc3713f2046e